Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart disease.
You are not logged in so some information on this page has been withheld. To see more, please log in.